Ageing is characterised by progressive functional decline across multiple biological systems. Anti-ageing research focuses on understanding and intervening in the cellular and molecular processes driving ageing to extend healthspan (years lived in good health) and potentially lifespan. This guide covers the science of ageing, peptide interventions, and research applications targeting senescence, mitochondrial function, telomerase activation, and longevity pathways.
The Ageing Problem Life expectancy has increased dramatically (from ~50 years in 1900 to ~80+ years today), but healthspan improvements lag behind. Most people spend their final years with age-related disease and functional decline:
- Muscle loss (sarcopenia)
- Bone loss (osteoporosis)
- Cognitive decline
- Cardiovascular disease
- Metabolic dysfunction
- Immune decline
- Cancer incidence
The Ageing Opportunity Unlike treating individual diseases (approach 1 disease at a time), targeting ageing itself addresses multiple conditions simultaneously. If ageing can be slowed or reversed, multiple age-related diseases improve together.
Key Ageing Mechanisms Research has identified 10 hallmarks of ageing:
- Genomic instability: DNA damage accumulation
- Telomere attrition: Chromosome end shortening
- Epigenetic alterations: Gene expression pattern changes
- Loss of proteostasis: Protein misfolding and aggregation
- Mitochondrial dysfunction: Energy production decline, ROS increase
- Cellular senescence: Cells stop dividing but remain active
- Stem cell exhaustion: Regenerative capacity loss
- Altered intercellular communication: Immune, metabolic signalling changes
- Disable macroautophagy: Cellular waste clearance impairment
- Altered nutrient sensing: mTOR, SIRT, AMPK dysregulation
Plus 4 emerging hallmarks being actively researched.
Peptide Approaches to Anti-Ageing Rather than targeting one hallmark, peptides often target multiple hallmarks simultaneously:
- NAD+: Restores mitochondrial function, activates sirtuins (longevity pathways)
- Epithalon: Activates telomerase, reverses cellular senescence
- Follistatin: Builds muscle (sarcopenia reversal), may enhance metabolic health
- SS-31: Targets mitochondria directly, reduces ROS
- Semax/Selank: Enhance BDNF, protect brain from age-related decline
The Science of Ageing
Telomere Shortening & Telomerase
Telomeres are protective caps at chromosome ends that shorten with each cell division (~50–200 bp per division). After 50–70 divisions (Hayflick limit), telomeres become critically short, triggering senescence (cell cycle arrest).
Telomerase Mechanism:
- Telomerase is a ribonucleoprotein enzyme that extends telomeres
- Contains RNA template (TERC) and protein reverse transcriptase (TERT)
- Active in germ cells, stem cells, some immune cells
- Largely inactive in somatic cells → progressive telomere shortening
Epithalon and Telomerase:
- Epithalon (tetrapeptide Ala-Glu-Asp-Gly) upregulates telomerase expression
- Increases TERT mRNA and protein levels
- Restores telomerase activity in cells with short telomeres
- Extends cellular lifespan in vitro
- May reverse senescence in aged tissues
Research Implications: Restoring telomerase activity selectively in somatic tissues (without cancer risk) could theoretically extend cellular lifespan and reverse age-related tissue decline.
Mitochondrial Dysfunction & ROS
Mitochondria are cellular “power plants” producing ATP (energy). With age:
- Mitochondrial DNA (mtDNA) accumulates mutations
- Oxidative phosphorylation efficiency declines
- Reactive oxygen species (ROS) increase
- ATP production falls
- ROS causes further damage (vicious cycle)
SS-31 (Elamipretide) Mechanism:
- Targets mitochondrial inner membrane
- Crosses blood–brain barrier and BBB
- Reduces cardiolipin oxidation (critical lipid)
- Decreases ROS production
- Restores ATP synthesis efficiency
- Protects against ischemia-reperfusion injury
NAD+ Metabolism:
- NAD+ is critical cofactor for sirtuins (SIRT1–7) and PARPs
- Sirtuins are “longevity genes”; activate upon caloric restriction
- SIRT1: ↑ mitochondrial biogenesis, ↑ autophagy, ↑ stress resistance
- SIRT6: ↑ genomic stability, ↑ immune function
- NAD+ levels decline with age; restoring them activates sirtuins
Research Model: NAD+ precursors or NAD+ itself upregulate sirtuin signalling, slowing multiple ageing hallmarks simultaneously.
Cellular Senescence & SASP
Senescent cells are permanently growth-arrested but metabolically active. Characteristics:
- Cease cell division
- Remain metabolically active (energy-consuming)
- Produce pro-inflammatory factors (IL-6, IL-8, TNF-α, etc.) — “senescence-associated secretory phenotype” (SASP)
- Accumulate with age; can comprise 15–20% of old tissue
- Contribute to inflammageing and age-related disease
Senolytic vs. Senostatic Approaches:
- Senolytic: Kill senescent cells (cellular suicide induction)
- Senostatic: Inhibit senescence formation (prevent cells from becoming senescent)
Epithalon as Senostatic:
- Prevents senescence induction by restoring telomerase and reducing stress
- Allows continued cell division in aged tissues
- Maintains tissue regenerative capacity
Stem Cell Exhaustion
Stem cells are reservoirs of regenerative capacity. With age:
- Stem cell numbers decline
- Stem cell function decreases
- Regenerative capacity plummets
- Tissue turnover slows
Peptide Support for Stem Cells:
- Growth factors (IGF-1, HGF, VEGF): Enhance stem cell proliferation and differentiation
- BDNF (via Semax/Selank): Supports neurogenic stem cells in brain
- NAD+ restoration: Enhances mitochondrial function in stem cells
Inflammageing & Immune Senescence
Inflammageing is chronic, low-grade systemic inflammation in aged individuals. Drivers:
- Senescent cell SASP (pro-inflammatory secretion)
- Altered gut microbiota composition
- Reduced regulatory T-cells (Tregs)
- Thymic involution (less T-cell production)
Anti-Inflammatory Peptides:
- Epithalon: Reduces SASP through senescence prevention
- Thymosin Alpha 1: Enhances T-cell production and function; supports Tregs
- Selank: GABAergic and immune-modulating; reduces stress-driven inflammation
- BPC-157, TB500: Pro-angiogenic and anti-inflammatory; support tissue repair
Relevant Peptides for Anti-Ageing Research
Table: Peptides Targeting Ageing Hallmarks
| Peptide | Primary Hallmark(s) | Mechanism | Secondary Benefits | Typical Dose |
|---|---|---|---|---|
| NAD+ | Altered nutrient sensing, Mitochondrial | SIRT activation, NAD+ restoration | Energy ↑, cognition | 250–1000 mg/day |
| Epithalon | Telomere attrition, Senescence | Telomerase ↑, senescence reversal | Hormonal balance, sleep | 10–50 mg/dose |
| Follistatin | Stem cell exhaustion, Sarcopenia | Myostatin ↓, muscle growth | Metabolic health | 0.1–1 mg/kg |
| SS-31 | Mitochondrial, ROS | Mitochondrial cardiolipin, ROS ↓ | Cardioprotection | 0.1–1 mg/kg |
| Semax | Altered communication, Brain ageing | BDNF ↑, neuroprotection | Stress resilience, cognition | 0.1–0.5 mg/day |
| Selank | Altered communication, Inflammageing | BDNF ↑, GABAergic, immune | Anxiety ↓, mood | 0.1–0.5 mg/day |
| Thymosin Alpha 1 | Immune senescence | T-cell activation, Treg support | Vaccine response, pathogen defence | 0.1–1 mg/kg/week |
| BPC-157 | Altered communication, Tissue repair | Anti-inflammatory, VEGF-like | Wound healing, gut | 0.1–1 mg/kg/day |
| HGH / IGF-1 | Stem cell, Sarcopenia | Growth factors, protein synthesis | Body composition, bone | 0.2–1 IU/kg/week |
Synergistic Combinations for Comprehensive Anti-Ageing:
| Combination | Rationale | Target Hallmarks |
|---|---|---|
| NAD+ + Epithalon | Mitochondrial + telomerase pathways | Mitochondrial, telomere, senescence |
| NAD+ + Follistatin | Metabolic restoration + muscle preservation | Nutrient sensing, stem cell, sarcopenia |
| Semax + Selank + Epithalon | Brain + immune + cellular senescence | Brain ageing, immune, senescence |
| SS-31 + NAD+ | Mitochondrial focus (dual mechanism) | Mitochondrial, ROS, nutrient sensing |
| HGH + Epithalon + BPC-157 | Systemic regeneration | Stem cell, muscle, tissue repair, senescence |
Research Protocols & Models
In Vitro Senescence Models
Primary Human Fibroblasts (Replicative Senescence):
- Culture cells from young and old donors
- Monitor telomere length (qPCR, FISH)
- Measure senescence markers (p16, p21, SA-β-gal)
- Treat with peptides; assess lifespan extension
- Readouts: Cell divisions before senescence, senescence marker reduction
- Cost: Moderate; physiologically relevant
Induced Pluripotent Stem Cells (iPSCs):
- Create age-accelerated iPSCs
- Treat with peptides (NAD+, Epithalon)
- Measure telomerase activity, telomere length
- Assess stemness markers
- Readouts: Telomerase reactivation, senescence reversal
- Cost: High; very relevant for regenerative research
In Vivo Ageing Models
Aged Rodents (Chronological Ageing):
- C57BL/6 mice, 18–24+ months old (“old mice”)
- Treat with peptides (Epithalon, NAD+, Semax)
- Measure:
- Physical function (grip strength, treadmill endurance)
- Cognitive function (Morris water maze, fear conditioning)
- Tissue senescence (p16 immunofluorescence, SA-β-gal staining)
- Mitochondrial function (oxygen consumption, ATP production)
- Immune function (T-cell proliferation, vaccine response)
- Timeline: 8–16 weeks
- Advantages: True ageing model; lifespan extension measurable
- Limitations: Long timelines; expensive housing
Premature Ageing Models (PROGERIA, Werner Syndrome Mouse Models):
- Genetic models with accelerated ageing
- Dramatically shortened lifespans (months vs. years)
- Peptide efficacy more rapidly observable
- Good for mechanism validation
- Less relevant for normal ageing (extreme phenotype)
Cellular Senescence Burden Models:
- Induce senescence (doxorubicin, radiation, replicative stress)
- Treat with senolytic (kill senescent cells) or senostatic (prevent senescence) peptides
- Measure:
- Senescent cell percentage (p16+, SA-β-gal+)
- Tissue function recovery
- SASP marker reduction (IL-6, IL-8, TNF-α)
- Timeline: 2–4 weeks
- Advantages: Rapid assessment of senescence reversal
- Limitations: Artificial senescence induction
Expected Outcomes & Metrics
Primary Longevity Readouts:
- Lifespan: Median and maximum lifespan extension (months in mice, years in long-lived species)
- Healthspan: Lifespan spent in good health (functional capacity assessment)
- Age-Adjusted Mortality: Mortality rate relative to chronological age
Physical Function Metrics:
- Grip Strength: Proxy for overall muscle and organismal health
- Treadmill Endurance: Aerobic capacity and mitochondrial function
- Spontaneous Activity: Locomotor activity in home cage (energy)
- Balance & Coordination: Rotarod test
- Gait Analysis: Speed, stride length (motor function)
Cognitive Metrics:
- Morris Water Maze: Spatial memory (hippocampal-dependent)
- Fear Conditioning: Contextual and cued memory
- Novel Object Recognition: Working memory
- BDNF Levels: Brain BDNF protein (Semax/Selank marker)
Cellular & Molecular Markers:
- Telomere Length: qPCR, FISH (Epithalon marker)
- Telomerase Activity: TRAP assay (telomerase-positive cells)
- p16/p21 Expression: Senescence markers (immunofluorescence, qPCR)
- SA-β-gal Staining: Senescence-associated β-galactosidase (histology)
- NAD+ Levels: HPLC, enzymatic assay
- ATP Production: Mitochondrial oxygen consumption, ATP synthase activity
- ROS Levels: DCFDA fluorescence, DHE staining
- SIRT1/SIRT6 Activity: Immunoassay, gene expression (NAD+ markers)
Immune Function:
- T-Cell Count: Flow cytometry (CD4+, CD8+, Treg percentages)
- Vaccine Response: Antibody titres to vaccine antigens
- Pathogen Clearance: Bacterial/viral challenge models
Timeline of Effects:
- Acute (days–weeks): Gene expression changes, signalling activation, metabolic shifts
- Early (4–8 weeks): Tissue function improvements, senescence marker reduction
- Intermediate (8–16 weeks): Physical function gains, cognition improvements
- Long-term (16+ weeks): Lifespan extension observable (chronic treatment)
Recent Research Highlights
2023–2024 Research Focus:
- Epithalon efficacy in reversing senescence in aged tissues
- NAD+ restoration and sirtuin activation in longevity
- Semax neuroprotection in age-related cognitive decline
- Follistatin reversal of sarcopenia in aged rodents
- Combination peptide protocols for maximal healthspan extension
- Sex-specific responses to anti-ageing peptides (emerging)
- Epigenetic clock reversal with senescence-targeting peptides
FAQ
Q: Can peptides actually reverse ageing? A: Peptides can slow ageing markers and improve function in research models, but “reversal” is complex. Epithalon can extend cellular lifespan by restoring telomerase. NAD+ restoration improves mitochondrial function. Senescence-targeting peptides reduce age-related dysfunction. However, complete reversal (to young biological age) hasn’t been demonstrated—improvement and slowdown are more accurate descriptions.
Q: What’s the difference between lifespan and healthspan? A: Lifespan is total years lived. Healthspan is years lived in good health. Most anti-ageing research prioritises healthspan (functional life extension), which may be more realistic than lifespan extension in humans.
Q: Do anti-ageing peptides work in humans? A: Most anti-ageing peptide data comes from animal models. Human clinical trials are limited but promising. Epithalon, Semax, and others have clinical research support, but large-scale human trials specifically for lifespan/healthspan are lacking.
Q: Can I stack anti-ageing peptides for better results? A: Yes, stacking complementary peptides (e.g., NAD+ + Epithalon + Semax) targets multiple ageing hallmarks simultaneously. This multi-target approach may be more effective than single peptides, though research on specific combinations is limited.
Q: How long before I see anti-ageing benefits? A: Timelines vary:
- Acute (days): Gene expression, signalling changes (not visible)
- Early (4–8 weeks): Energy levels, physical function improvements
- Intermediate (8–16 weeks): Cognitive improvements, tissue regeneration
- Long-term (6–12+ months): Significant biological age reduction (estimated via epigenetic clocks)
Related Resources
Key Research Areas:
- Telomerase biology and cellular senescence
- NAD+ metabolism and sirtuin pathways
- Mitochondrial function and ROS
- Epigenetic clocks and ageing hallmarks
- Senescence-associated secretory phenotype (SASP)
- Inflammageing and immune senescence
Recommended Reading:
- Cell Journal: “The Hallmarks of Aging” — Foundational review
- Nature Aging — Current research
- Aging Cell — Peer-reviewed journal
- Gerontology Research — Clinical ageing research
CTA & Support
Explore Anti-Ageing Peptides
Browse our selection of longevity-focused peptides (NAD+, Epithalon, Follistatin, SS-31, Semax, Selank), all third-party tested with COAs.
Questions About Longevity Research?
Our support team can help with:
- Selecting peptides for anti-ageing research
- Designing multi-peptide longevity protocols
- Understanding telomerase vs. sirtuin pathways
- Interpreting senescence markers
- Combining peptides for systemic anti-ageing